BRCA2 and non-small cell lung carcinoma: In NSCLC, AAbs panels associated with autoimmune diseases (antinuclear, thyroglobulin, thyroid peroxidase AAbs) (20) and solely AAb (such as lgM-RF (21), NY-ESO-1, XAGE1 (22), p53, BRCA2, HUD, and tripartite motif-containing-21 (TRIM21) AAbs (23)) have been reported to be associated with ICIs therapy efficacy.